Aeon Global Health™ Adds 4 New Drug Classes and 17 New Medications to its Pharmacogenomics Test
June 21 2016 - 4:00PM
Expanded menu now covers over 200
medications and over 30 classes of drugs tested - making it one of
the most extensive test menus on the market
Authentidate Holding Corp. (OTC:ADAT), through its wholly owned
subsidiary, Aeon Global Health, which provides toxicology and
genetic testing services and secure, web-based software
applications and telehealth products for healthcare organizations,
today announced it added 4 new drug classes and 17 new medications
to its existing pharmacogenomics test, which is used to identify
how variations in a person’s genes influence how that individual
metabolizes and responds to different types of pharmaceutical
products. The expansion is a significant enhancement and brings the
test list to over 200 medications and over 30 classes of drugs –
making Aeon Global Health’s pharmacogenomics offering one of the
most extensive test menus on the market.
The new drug classes include:
- Angiotensin II Receptor Antagonists (used to treat conditions
such as high blood pressure and heart failure);
- Diuretics (used to treat conditions in which there is excess
body water and for the treatment of high blood pressure);
- Antimalarials (used to treat and prevent malaria);
- Meglitinides (used to treat type 2 diabetes).
Additional medications were also added to the new drug classes
already in the pipeline.
This information enables physicians to prescribe the safest and
most effective pharmaceutical products for their patients.
Pharmacogenomics testing offers an alternative to the
trial-and-error method of prescribing medications by identifying
the optimal drug based on the individual’s genetic makeup.
“Adverse drug reactions occur in more than two million
persons a year and cause more than 100,000 deaths annually as cited
by the Food and Drug Administration,” commented Bill Henry of Aeon
Global Health. “By considering a person’s genetic makeup, Aeon’s
growing menu of genetic testing enables healthcare professionals to
meaningfully reduce these dangerous adverse drug reactions, as well
as the costs associated with them to individuals, to health care
providers, and to society in general. Educating the public about
this test is crucial to understanding the benefits and cost
savings.”
In addition to the exciting pharmacogenomics test enhancements,
the combined ADAT business has achieved significant progress so far
this year. Some of the highlights include:
- The Company continues to be well positioned to participate in
the broad market trend towards personalized medicine;
- Added more than 220 new physician groups using our testing
services so far this year;
- The deep genetic testing experience the Company has developed
over the last few years has been invaluable as it completes the
validation of several new genetic tests which it expects to launch
over the next four months;
- The Company is investing resources in its genetic testing
pipeline and expects to significantly expand its portfolio of
genetic tests over the next twelve months.
Bill Henry of Aeon Global Health, added, “We have achieved a
number of important accomplishments over the last twelve months and
are well positioned to address the large market opportunity over
the next several years. Our executive team and Board of Directors
believe our current share price does not reflect the significant
underlying value of our business. We look forward to
completing the proxy process by holding a Special Meeting of
Stockholders on July 11, 2016 and remain excited about our business
plan. The executive team and our board continue to be personally
invested in positive outcomes for our business.”
ABOUT AEON GLOBAL HEALTH
Aeon Global Health is one of the fastest growing clinical
laboratories and healthcare services organizations in the U.S.
offering diagnostic services in Cancer Genomics, Toxicology,
Pharmacogenomics, and Health Technology Applications. Aeon leads
the market in scientific innovation and client partnerships.
Founded in 2011, Aeon is first in healthcare technology research
and development where our proprietary methodologies provide
expedited and highly accurate urine and oral fluid (saliva) test
results. Our executive leadership and Ph.D. scientists offer
decades of expertise from the field. We provide our partner
healthcare professionals with customized service plans to maximize
the effective delivery of care.
Media Contact:
James Carbonara, Hayden IR
James@haydenir.com or (646) 755-7412